Crossject (ALCJ) - Total Liabilities

Latest as of December 2025: €35.30 Million EUR ≈ $41.27 Million USD

Based on the latest financial reports, Crossject (ALCJ) has total liabilities worth €35.30 Million EUR (≈ $41.27 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Crossject - Total Liabilities Trend (2010–2025)

This chart illustrates how Crossject's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Crossject's working capital to evaluate short-term liquidity relative to the company's equity base.

Crossject Competitors by Total Liabilities

The table below lists competitors of Crossject ranked by their total liabilities.

Company Country Total Liabilities
Mdevice
KQ:226590
Korea ₩68.93 Billion
Kino Polska TV SA
WAR:KPL
Poland zł114.56 Million
Thai Optical Group Public Company Limited
BK:TOG
Thailand ฿2.15 Billion
Grupo Ortiz Properties Socimi
MC:YGOP
Spain €101.27 Million
Luda Technology Group Limited
NYSE MKT:LUD
USA $26.24 Million
Piscines Desjoyaux SA
PA:ALPDX
France €58.08 Million
District Metals Corp
V:DMX
Canada CA$493.27K
Lyko Group A
ST:LYKO-A
Sweden Skr2.05 Billion

Liability Composition Analysis (2010–2025)

This chart breaks down Crossject's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALCJ company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.35 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -7.24 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.16 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Crossject's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Crossject (2010–2025)

The table below shows the annual total liabilities of Crossject from 2010 to 2025.

Year Total Liabilities Change
2025-12-31 €35.30 Million
≈ $41.27 Million
+3.10%
2024-12-31 €34.24 Million
≈ $40.03 Million
+0.97%
2023-12-31 €33.91 Million
≈ $39.64 Million
+12.38%
2022-12-31 €30.17 Million
≈ $35.28 Million
-18.46%
2021-12-31 €37.01 Million
≈ $43.26 Million
+6.58%
2020-12-31 €34.72 Million
≈ $40.59 Million
+61.63%
2019-12-31 €21.48 Million
≈ $25.11 Million
+16.08%
2018-12-31 €18.50 Million
≈ $21.63 Million
+59.11%
2017-12-31 €11.63 Million
≈ $13.60 Million
+46.01%
2016-12-31 €7.97 Million
≈ $9.31 Million
+56.75%
2015-12-31 €5.08 Million
≈ $5.94 Million
+30.64%
2014-12-31 €3.89 Million
≈ $4.55 Million
-17.28%
2013-12-31 €4.70 Million
≈ $5.50 Million
+4.54%
2012-12-31 €4.50 Million
≈ $5.26 Million
-10.71%
2011-12-31 €5.04 Million
≈ $5.89 Million
-54.46%
2010-12-31 €11.06 Million
≈ $12.93 Million
--

About Crossject

PA:ALCJ France Medical Instruments & Supplies
Market Cap
$117.41 Million
€100.42 Million EUR
Market Cap Rank
#19177 Global
#288 in France
Share Price
€1.89
Change (1 day)
-0.74%
52-Week Range
€1.40 - €2.69
All Time High
€10.40
About

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more